Clinical Trial Search

Primary: Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms — 0.07; 1.03 event rate per 100 person-yr — p=<0.0001

Primary: Number of Participants in Each Condition With Optimal ART Adherence — 27; 29 participants

Primary: HIV Seroconversion — 48; 83 Participants — p=0.002

Primary: Number of Participants Who Stated (by Self-report) That They Had Side Effects — 1; 0; 2; 1 participants

Primary: Qualitative Summaries of Participant Experience in Focus Group Discussions — 100; 7; 26; 10 number of times reported in FGD

Primary: Engagement in Care (Implementation Component) — 1; 1 Participants

Primary: HIV Self-testing Knowledge — 3.24; 3.79 score on a scale

Primary: Maternal HIV Incidence — 0.38; 0.31 incidence/100 Person years

Primary: Proportion of Persons Agreeing to be Screened for Acute HIV Infection Among Those Offered Screening — 0.622 proportion of participants screened

Primary: Change in Condom Use Self-Efficacy (From Baseline to 1 Month Follow-up) — 4.4 score on a scale — p=<.001

Primary: Proportion of Condom Usage — .68; .56 proportion of condom use

Primary: Retention, Measured as the Number of HIV Exposure Events That Were Retained in Care at the 24 Week Follow-up Visit — 125; 157 HIV Exposure Events — p=<0.05

Primary: Incidence of HIV-1 Seroconversion Among HIV-1 Uninfected Participants — 0.65; 0.50; 1.99 events per 100 person years — p=<0.001

Primary: Illicit Drug Use Days — 1.49; .80; 1.16; 0.83 days — p=.433

Primary: Visits With PrEP Dispensation to Female Study Participants Reporting Sexual Behaviors or STI Symptoms — 211 Visits

Primary: Dried Blood Spot Analysis of Medication Adherence- Mother and Infant — 56; 157; 35; 183 Participants

Primary: Systolic Blood Pressure — 134.9; 134.9; 129.9; 136.3 model estimated mmhg

Primary: Sex Risk Behaviors: Number of Sex Partners (>=2 Sex Partners) — 17; 29; 50; 53 participants — p=<0.01

Primary: Number of Unprotected Acts of Intercourse — 19.7; 12.9; 18.2 # of unprotected sex acts at 12 months

Primary: The Safety Profile Associated With the Open-label Use of the Dapivirine Vaginal Matrix Ring (25 mg) in Women — 52; 19; 2 Participants

Primary: Adolescent Sexual Activity Index — 1.39; 1.45; 2.12; 1.90 score on a scale — p=0.62

Primary: Adherence to PrEP — 22; 11; 30; 54 Participants

Primary: Change in Prevention Self-efficacy — 1.87; 0.20 score on a scale — p=0.04

Primary: Self-reported Consistent Condom Use During Vaginal Intercourse in the Past 3 Months — 121; 103; 125; 93 Participants — p=.008

Primary: Feasibility Assessed Using Change in Retention Rates — 97.5; 97.4; 97.5; 100 percentage of questionnaires returned

Primary: Percentage of Participants With Adverse Drug Reactions in the Tenofovir/Emtricitabine and Placebo Arms — 91.2; 88.2 percentage of participants with AE — p=0.003

Primary: Retention Rate — 20; 24 Participants

Primary: Person-years of Follow-up of Tenofovir 1% Gel and Vaginal Placebo Gel Arms — 1024; 1030 person-years

Primary: Initiation of PrEP — 18; 21 Participants

Primary: Number of AGYW Who Tested Positive for a Sexually Transmitted Infection (STI) — 4; 6 Participants — p=0.15